Incyte Corporation (NASDAQ:INCY).
On July 13 analysts at RBC Capital starting coverage on the stock with an initial rating of “Outperform”. BMO Capital added INCY to its research portfolio by announcing an initial rating of “Outperform”.
Equity analyst Morgan Stanley began coverage with a rating of “Overweight” and setting a price target of $85.00. February 16 investment analysts at Leerink Swann left the company rating at “Outperform” but lowered the price target to $94.00 from $118.00.
On February 12 Brean Capital held the stock rating at “Buy” but lowered the price expectation from $131.00 to $92.00.
The company is trading up by 4.64% since yesterday’s close of $89.07. Shares last traded at $93.20 which is just over the 50 day moving average which is $82.31 and a bit higher than the 200 day moving average of $79.52. The 50 day moving average went up by +13.22% and the 200 day average went up $13.68 or +17.20%.
The P/E ratio is currently 253.26 and market capitalization is 17.52B. In the last earnings report the EPS was $0.37 and is projected to be $0.19 for the current year with 188,002,000 shares presently outstanding. Next quarter’s EPS is forecasted to be $-0.10 with next year’s EPS projected to be $1.36.
Traders are feeling more bearish on Incyte Corporation looking at the rise in short interest. The firm saw a rise in short interest of 0.03% as of the latest report on September 15, 2016. Short shares grew 144,293 over that timeframe. Days to cover increased from 3.5 to 4.3 and the short interest percentage is 0.03% as of September 15.